Treatments for Medullary Thyroid Cancer Compared to Metastatic Medullary Thyroid Cancer
DOI:
https://doi.org/10.58445/rars.1317Keywords:
Medullary thyroid cancer, Cancer treatment, Chemotherapy, Targeted treatment, Cancer treatments, Tyrosine kinase inhibitorsAbstract
Medullary thyroid cancer, or MTC, is a subtype of thyroid cancer that originates from the C-cells in the thyroid. This type of thyroid cancer is not the most common or the most deadly, however, little is known about MTC as compared to the more common types of thyroid cancer. Once MTC has metastasized it can be called metastatic medullary thyroid cancer. The most common sites of metastasis are nearby the thyroid, such as the lymph nodes, but there have been cases of MTC traveling further into the body. This paper was created to explore the differences between treating medullary thyroid cancer and metastatic medullary thyroid cancer. When cancer metastasizes, it does not lose its cellular identity, therefore the treatments should be similar. An extensive analysis of scientific research was used to compare treatment options for MTC and metastatic MTC. Having extensive knowledge of the variability of treatments for MTC and metastatic MTC can help medical professionals better treat patients in the future. It can also help researchers and drug companies develop newer more effective pharmaceuticals. Using this knowledge can help future scientists develop more advanced treatments for other types of metastatic cancers as well.
References
Dictionary of cancer terms. (n.d.). Retrieved June 20, 2024, from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/c-cell
CARTER, D. (2022, November 7). RET inhibitors: A treatment for any RET-altered cancer. MD Anderson Cancer Center. Retrieved June 20, 2024, from https://www.mdanderson.org/cancerwise/ret-inhibitors--a-treatment-for-any-ret-altered-cancer.h00-159544479.html
Boucai, L., Zafereo, M., & Cabanillas, M. E. (2024). Thyroid cancer [Review [Title of Reviewed Work]]. JAMA, 331(5). https://doi.org/10.1001/jama.2023.26348
Cleveland Clinic. (n.d.). Medullary Thyroid Cancer. Cleveland Clinic. Retrieved June 26, 2024, from https://my.clevelandclinic.org/health/diseases/22873-medullary-thyroid-cancer-mtc
National Cancer Institute. (2016, December 15). Definitions of TNM Stages for MTC [Table]. NCBI. https://www.ncbi.nlm.nih.gov/books/NBK65719.5/table/CDR0000062913__560/?report=objectonly
National Cancer Institute. (n.d.). Cancer Staging. In Diagnosis and Staging. Retrieved June 26, 2024, from https://www.cancer.gov/about-cancer/diagnosis-staging/staging#:~:text=Regional%E2%80%94Cancer%20has%20spread%20to,to%20figure%20out%20the%20stage
Yeh, T., Yeung, M., Sherman, E. J., Tuttle, R. M., & Sabra, M. M. (2020). Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Thyroid : official journal of the American Thyroid Association, 30(8), 1112–1119. https://doi.org/10.1089/thy.2019.0579
The American Cancer Society. (n.d.). Thyroid Cancer Risk Factors. American Cancer Society. Retrieved June 26, 2024, from https://www.cancer.org/cancer/types/thyroid-cancer/causes-risks-prevention/risk-factors.htm l
Khatami, F., & Tavangar, S. M. (2018). Genetic and Epigenetic of Medullary Thyroid Cancer. Iranian biomedical journal, 22(3), 142–150. https://doi.org/10.22034/ibj.22.3.142
Park, H., Yang, H., Heo, J., Kim, T. H., Kim, S. W., & Chung, J. H. (2021). Long-Term Outcomes and Causes of Death among Medullary Thyroid Carcinoma Patients with Distant Metastases. Cancers, 13(18), 4670. https://doi.org/10.3390/cancers13184670
Kazakou, P., Simeakis, G., Alevizaki, M., & Saltiki, K. (2021). Medullary thyroid carcinoma (MTC): unusual metastatic sites. Endocrinology, diabetes & metabolism case reports, 2021, 21-0063. Advance online publication. https://doi.org/10.1530/EDM-21-0063
Roman, S., Lin, R. and Sosa, J.A. (2006), Prognosis of medullary thyroid carcinoma. Cancer, 107: 2134-2142. https://doi.org/10.1002/cncr.22244
Zhang, D., Colombo, C., Sun, H., Kim, H. Y., Pino, A., De Leo, S., Gazzano, G., Persani, L., Dionigi, G., & Fugazzola, L. (2022). Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines. Frontiers in endocrinology, 13, 875875. https://doi.org/10.3389/fendo.2022.875875
Hadoux, J., & Schlumberger, M. (n.d.). Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer. Science Direct. http://dx.doi.org/10.1016/j.beem.2017.04.009
The American Cancer Society. (n.d.). Chemotherapy for Thyroid Cancer. American Cancer Society. Retrieved June 26, 2024, from https://www.cancer.org/cancer/types/thyroid-cancer/treating/chemotherapy.html#:~:text=The%20chemotherapy%20drugs%20most%20commonly,Cyclophosphamide
Nocera, M., Baudin, E., Pellegriti, G., Cailleux, A., Mechelany-Corone, C., Schlumberger, M., & Groupe d'Etude des Tumeurs à Calcitonine. (2000). Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. NCBI. Retrieved June 26, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363532/pdf/83-6691314a.pdf
Wells, S. A., Jr, Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., Raue, F., Frank-Raue, K., Robinson, B., Rosenthal, M. S., Santoro, M., Schlumberger, M., Shah, M., Waguespack, S. G., & American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association, 25(6), 567–610. https://doi.org/10.1089/thy.2014.0335
Priya, S. R., Dravid, C. S., Digumarti, R., & Dandekar, M. (2017). Targeted Therapy for Medullary Thyroid Cancer: A Review. Frontiers in oncology, 7, 238. https://doi.org/10.3389/fonc.2017.00238
Okafor, C., Hogan, J., Raygada, M., Thomas, B. J., Akshintala, S., Glod, J. W., & Del Rivero, J. (2021). Update on Targeted Therapy in Medullary Thyroid Cancer. Frontiers in endocrinology, 12, 708949. https://doi.org/10.3389/fendo.2021.708949
Brassard, M., & Rondeau, G. (2012). Role of vandetanib in the management of medullary thyroid cancer. Biologics : targets & therapy, 6, 59–66. https://doi.org/10.2147/BTT.S24220
Mass General Brigham. (2023). RET Gene. Retrieved June 26, 2024, from https://www.massgeneral.org/assets/mgh/pdf/cancer-center/genetics/ret-fact-sheet.pdf
Samuel A. Wells Jr, Bruce G. Robinson, Robert F. Gagel, Henning Dralle, James A. Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R. Vasselli, Jessica Read, Peter Langmuir, Anderson J. Ryan, & Martin J. Schlumberger. (n.d.). Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2011.35.5040
Winstead, E. (2023, November 15). Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers. National Cancer Institute. Retrieved June 26, 2024, from https://www.cancer.gov/news-events/cancer-currents-blog/2023/selpercatinib-ret-lung-medullary-thyroid#:~:text=Selpercatinib%20targets%20abnormal%20RET%20proteins,and%20vandetanib%2C%20new%20research%20suggests
Pelizzo, M. R., Mazza, E. I., Mian, C., & Merante Boschin, I. (2023). Medullary thyroid carcinoma. Expert Review of Anticancer Therapy, 23(9), 943–957. https://doi.org/10.1080/14737140.2023.2247566
Downloads
Posted
Categories
License
Copyright (c) 2024 Makena Columb
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.